Turku, Finland

Time filter

Source Type

The invention relates to a method and apparatus for detecting undesired measurement conditions in a sample container. The method comprises measuring a fluorescent property of the sample container comprising a sample substrate with impregnated blood sample and incubation buffer to which the blood sample is to be eluted, and determining, based on temporal and/or spectral characteristics of the fluorescent property, whether the fluorescent property is characteristic to a sample container comprising a sample substrate and incubation buffer under said undesired measurement conditions or to a sample container suitable for optical measurement of analyte contained in the sample. Thus undesired measurement condition can be a floating sample substrate or a foreign body in the sample container. By means of the invention, reliability of neonatal screening, for example, can be increased.


A method for predicting risk of gestational diabetes mellitus (GDM) in a pregnant individual includes measuring one or more biochemical markers in a blood sample obtainedfrom the pregnant individualto determine one or more biomarker levels, where the one or more measured biochemical markers includes at least one of Amylin, 17-Estradiol, and Lipocalin-2, identifying, for each of the one or more measured biochemical markers, a difference between the measured biomarker level and a corresponding predetermined control level, and, responsiveto the identifying, determining a prediction corresponding to a relative risk of the pregnantindividual having or developing GDM.


A device for detecting whether a sample well (352) contains a sample is presented. The sample well contains one or more fluorescent substances needed for an optical analysis of the sample. The device comprises a controller (312) configured to compute, on the basis of a luminescence, e.g. fluorescence, emission signal measured from the sample well (352), an indicator value indicative of a decay time of the measured fluorescence emission signal. The controller (312) is configured to compare the indicator value to a reference value and to set, in accordance with the comparison, a detection result to express that the sample well (352) contains the sample or that the sample well (352) does not contain the sample.


Patent
Wallac Oy | Date: 2017-07-12

The present description relates to a method for determining the risk of a pregnant woman with chronic hypertension developing early or late onset pre-eclampsia. The present description provides methods useful for determining risk that a pregnant individual with chronic hypertension will develop an early pre-eclampsia or late pre-eclampsia. Useful combination of biochemical markers including PlGF and sP-Selectin and related clinical population studies are described herein.


Patent
Wallac Oy | Date: 2017-07-26

The present invention relates to a method for determining risk of preterm birth (PTB) in a pregnant individual. The method comprises measuring in a biological sample obtained from the pregnant individual, levels of biomarkers AFP and free hCGbeta, and at least one biomarker selected from FSTL3, sTNR1, PlGF2, Activin A, Ue3 and sP-selectin and optionally cervical length; or levels of biomarkers AFP and free hCGbeta and cervical length, and determining a relative risk of the pregnant individual developing PTB. The invention relates also to a kit, apparatus and system for predicting risk of PTB.


Patent
Perkin Elmer Corporation, Wallac Oy and Foundation Medicine | Date: 2015-11-13

The disclosure relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual has for developing pre-eclampsia based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers. The disclosure also relates to methods, medical profiles, kits and apparatus for use in determining the risk that a pregnant individual is carrying a fetus having a chromosomal abnormality based on amounts of certain biochemical markers in a biological sample from the individual and biophysical markers.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.0-1 | Award Amount: 7.64M | Year: 2013

Project ASPRE is a commercially led development project that aims to boost translation of the results of PREGENESYS (FP6 EU #37244) into effective applications for prenatal care. PREGENESYS has identified several biomarkers for early (11-13 weeks gestation) and effective identification of pregnancies at high risk of developing pre-eclampsia (PE). This disorder affects 2-8% of pregnant women and is a major cause of short- and long-term maternal and perinatal morbidity and mortality. Studies under PREGENESYS using in-vitro research methods suggested that aspirin is the most promising agent for preventing PE. Evidence from small clinical studies has indicated that prophylactic use of low-dose aspirin starting before 16 weeks gestation can potentially halve the PE prevalence and its associated complications. Objectives: Widespread clinical implementation of a strategy of screening and prevention of PE: (1) Reduce the prevalence of PE requiring delivery before 37 weeks (preterm PE) by at least 50%, (2) Demonstrate through a large multicentre screening and prevention study the acceptability, uptake and efficacy of first trimester multi-parameter screening of preterm PE and its preventative treatment with aspirin, (3) Develop affordable, automated and reliable methods for high throughput measurement of biomarkers and commercial platforms for PE risk assessment software, (4) Develop management protocols for high risk and low risk pregnancies for PE, (5) Improve education and training of healthcare professionals involved in pregnancy care, (6) Conduct the dissemination and training required to drive clinical acceptance and adoption of multi-parameter PE screening and aspirin treatment. Expected results and impact: Generating a market demand for SME-based newly developed products for PE screening and prevention, including machines, kits and software, thereby transforming research success into economic growth for SMEs and upholding European leadership in perinatal care.


A method for predicting risk of pre-eclampsia in a pregnant individual includes measuring one or more biochemical markers including an RBP4 biochemical marker in a blood sample obtained from the pregnant individual to determine one or more biomarker levels including an RBP4 biomarker level, identifying, for each of the one or more measured biochemical markers, a difference between the measured biomarker level and a corresponding predetermined control level, and, responsive to the identifying, determining a prediction corresponding to a relative risk of the pregnant individual having or developing pre-eclampsia.


A device for managing a sample to be analyzed comprises magnetizing equipment (302) for producing magnetic field capable of interacting, when the sample is moving to or located in a sample well, with magnetically amplifying material attached to the sample, where the magnetically amplifying material has relative magnetic permeability constant greater than one. With the aid of the magnetizing element the movement of the sample to the sample well and/or the position of the sample in the sample well can be monitored and/or controlled. The device can be, for example but not necessarily, an instrument for dispensing samples to sample wells or an optical measurement instrument.


Patent
Wallac Oy | Date: 2016-03-22

The invention relates to a method and apparatus for detecting elution of a sample from a sample substrate to incubation buffer contained in a sample well while the sample substrate is still within the well. The method comprises measuring light absorption of the contents of the sample well at a predefined wavelength or wavelength range, and determining, based on the absorption measurement, the degree of elution of the sample. According to the invention, a wavelength or wavelength range is used which is absorbed by at least one elutable component of the sample but transmitted by the sample substrate. The invention provides a reliable way of determining the degree of elution of blood samples in neonatal screening, for example.

Loading Wallac Oy collaborators
Loading Wallac Oy collaborators